{"id":357457,"date":"2025-08-29T10:30:32","date_gmt":"2025-08-29T10:30:32","guid":{"rendered":"https:\/\/pocketoption.com\/blog\/how-to-buy-mediwound\/"},"modified":"2025-08-29T10:30:32","modified_gmt":"2025-08-29T10:30:32","slug":"how-to-buy-mediwound","status":"publish","type":"post","link":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/","title":{"rendered":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"content":{"rendered":"<div id=\"root\"><div id=\"wrap-img-root\">text<\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>text<\/p>\n","protected":false},"author":129,"featured_media":334009,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[12837],"tags":[40],"class_list":["post-357457","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-signal","tag-signal"],"acf":{"h1":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131","h1_source":{"label":"H1","type":"text","formatted_value":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131"},"description":"Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile MediWound Ltd. (MDWD) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin.","description_source":{"label":"Description","type":"textarea","formatted_value":"Bu yenilik\u00e7i biyoteknoloji \u015firketi i\u00e7in g\u00fcncel fiyat analizi, risk de\u011ferlendirmesi ve ad\u0131m ad\u0131m sat\u0131n alma s\u00fcreci ile MediWound Ltd. (MDWD) hisse senedine nas\u0131l yat\u0131r\u0131m yap\u0131laca\u011f\u0131n\u0131 \u00f6\u011frenin."},"intro":"Keskin t\u0131bbi yeniliklere yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? MediWound Ltd. (MDWD), biyoteknoloji ve yara bak\u0131m\u0131 alanlar\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor\u2014b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip bir sekt\u00f6r. Bu \u0130srailli \u015firket, ciddi yan\u0131klar ve kronik yaralar\u0131n tedavisinde devrim yarat\u0131yor ve t\u0131bbi ilerlemeye inanan yat\u0131r\u0131mc\u0131lar i\u00e7in b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Mevcut hisse performans\u0131ndan ilk yat\u0131r\u0131m\u0131n\u0131z\u0131 yapman\u0131n pratik ad\u0131mlar\u0131na kadar her \u015feyi ke\u015ffedece\u011fiz.","intro_source":{"label":"Intro","type":"text","formatted_value":"Keskin t\u0131bbi yeniliklere yat\u0131r\u0131m yapmay\u0131 m\u0131 d\u00fc\u015f\u00fcn\u00fcyorsunuz? MediWound Ltd. (MDWD), biyoteknoloji ve yara bak\u0131m\u0131 alanlar\u0131n\u0131n heyecan verici kesi\u015fimini temsil ediyor\u2014b\u00fcy\u00fck b\u00fcy\u00fcme potansiyeline sahip bir sekt\u00f6r. Bu \u0130srailli \u015firket, ciddi yan\u0131klar ve kronik yaralar\u0131n tedavisinde devrim yarat\u0131yor ve t\u0131bbi ilerlemeye inanan yat\u0131r\u0131mc\u0131lar i\u00e7in b\u00fcy\u00fcleyici bir f\u0131rsat sunuyor. Mevcut hisse performans\u0131ndan ilk yat\u0131r\u0131m\u0131n\u0131z\u0131 yapman\u0131n pratik ad\u0131mlar\u0131na kadar her \u015feyi ke\u015ffedece\u011fiz."},"body_html":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2> <p>29 A\u011fustos 2025 itibar\u0131yla, MediWound Ltd. (MDWD) NASDAQ borsas\u0131nda <strong>17,25 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize i\u015faretleyin: <strong>25 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih.<\/p> <h3>25 Kas\u0131m Neden Bu Kadar \u00d6nemli<\/h3> <p>MediWound, kazan\u00e7 tarihleri \u00e7evresinde dramatik fiyat hareketleri g\u00f6sterdi. \u015eirketin 14 A\u011fustos 2025'teki son 2. \u00e7eyrek raporu, g\u00fc\u00e7l\u00fc %43 \u00e7eyrekten \u00e7eyre\u011fe gelir art\u0131\u015f\u0131yla 5,7 milyon $'a ula\u015fmas\u0131na ra\u011fmen \u00f6nemli volatiliteye neden oldu (<a href=\"https:\/\/www.nasdaq.com\/articles\/mediwound-revenue-jumps-43-q2\">Nasdaq Raporu<\/a>).<\/p> <p>Tarihsel kazan\u00e7 tepkileri ilgin\u00e7 bir desen ortaya koyuyor:<\/p> <ul> <li><strong>2025 2. \u00c7eyrek (14 A\u011fu)<\/strong>: Gelir beklentileri a\u015fmas\u0131na ra\u011fmen, net zararlar\u0131n geni\u015flemesi nedeniyle hisse bask\u0131 alt\u0131nda kald\u0131<\/li> <li><strong>2025 1. \u00c7eyrek (21 May)<\/strong>: EPS -0,07 ile -0,66 tahminlerini %89,39 a\u015farak olumlu kazan\u00e7 s\u00fcrprizi<\/li> <li><strong>2024 4. \u00c7eyrek (19 Mar)<\/strong>: Beklentileri %40,98 a\u015fmas\u0131na ra\u011fmen hemen fiyat \u00fczerinde s\u0131n\u0131rl\u0131 etki<\/li> <\/ul> <p>Bu desen, MediWound'un genellikle kazan\u00e7 tahminlerini a\u015fmas\u0131na ra\u011fmen, piyasan\u0131n \u00e7eyreklik finansal metriklerden ziyade uzun vadeli klinik geli\u015fmelere daha g\u00fc\u00e7l\u00fc tepki verdi\u011fini g\u00f6steriyor.<\/p> [cta_green text=\"Ticarete Ba\u015fla\"]<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2> <p>MediWound'un hissesi son alt\u0131 ayda klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc \u00f6nemli volatilite ya\u015fad\u0131:<\/p> <ul> <li><strong>\u015eubat-Mart 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken hisse 14-16 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li> <li><strong>Nisan-May\u0131s 2025<\/strong>: Olumlu 1. \u00e7eyrek kazan\u00e7 s\u00fcrprizi sonras\u0131 18-20 $ aral\u0131\u011f\u0131na s\u0131\u00e7rad\u0131<\/li> <li><strong>Haziran-Temmuz 2025<\/strong>: Piyasa \u00fcretim geni\u015fleme haberlerini sindirirken 17-19 $ civar\u0131nda konsolide oldu<\/li> <li><strong>A\u011fustos 2025<\/strong>: Mevcut 17,25 $ seviyesi kar\u0131\u015f\u0131k 2. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 yans\u0131t\u0131yor\u2014g\u00fc\u00e7l\u00fc gelir ama daha geni\u015f zararlar<\/li> <\/ul> <p>Genel e\u011filim <strong>%17,70 ayl\u0131k d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6sterse de, bu durum \u015firketin gelecekteki b\u00fcy\u00fcmeye a\u011f\u0131r yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131 gizliyor (<a href=\"https:\/\/www.tradingview.com\/symbols\/NASDAQ-MDWD\/\">TradingView Verileri<\/a>). Bu volatilite, dikkatli yat\u0131r\u0131mc\u0131lar i\u00e7in hem risk hem de f\u0131rsat yarat\u0131yor.<\/p> <h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2> <p>Mevcut analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p> <ul> <li><strong>2025 Y\u0131l Sonu<\/strong>: 25-30 $ aral\u0131\u011f\u0131 (%45-75 y\u00fckseli\u015f potansiyeli) <ul> <li>\u00dcretim \u00f6l\u00e7eklendirme tamamlanmas\u0131yla destekleniyor<\/li> <li>EscharEx Faz III deneme ilerleme g\u00fcncellemeleri<\/li> <li>Olas\u0131 ortakl\u0131k geni\u015flemeleri<\/li> <\/ul> <\/li> <li><strong>2026 Hedefi<\/strong>: 35-40 $ aral\u0131\u011f\u0131 <ul> <li>EscharEx Faz III verilerinin 2026 ortas\u0131nda beklenmesi kritik y\u0131l<\/li> <li>\u00dcretim kapasitesinin tam kullan\u0131m\u0131<\/li> <li>Olas\u0131 uluslararas\u0131 pazar geni\u015flemeleri<\/li> <\/ul> <\/li> <li><strong>2028 Projeksiyonu<\/strong>: 50-60 $ aral\u0131\u011f\u0131 <ul> <li>EscharEx'in ba\u015far\u0131l\u0131 ticarile\u015fmesi varsay\u0131m\u0131<\/li> <li>Kronik yara bak\u0131m segmentinde pazar penetrasyonu<\/li> <li>Olas\u0131 ek \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri<\/li> <\/ul> <\/li> <li><strong>2030 Vizyonu<\/strong>: 75-100+ $ aral\u0131\u011f\u0131 <ul> <li>Enzimatik debridman alan\u0131nda yerle\u015fik liderlik<\/li> <li>B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/li> <li>\u00c7oklu endikasyonlarda k\u00fcresel pazar geni\u015flemesi<\/li> <\/ul> <\/li> <\/ul> <p><strong>Sonu\u00e7<\/strong>: 2-3 y\u0131ll\u0131k ufku olan risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/p> <h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Yat\u0131r\u0131m Yapmadan \u00d6nce Bilin<\/h2> <h3>Y\u00fcksek Volatilite Riskleri<\/h3> <ul> <li>Biyoteknoloji hisseleri tek haber olaylar\u0131nda %20-30 dalgalanabilir<\/li> <li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 hisse fiyat\u0131n\u0131 y\u0131kabilir<\/li> <li>32,9M $ nakit t\u00fcketimi sadece 16-18 ayl\u0131k \u00e7al\u0131\u015fma sermayesi sa\u011fl\u0131yor (<a href=\"https:\/\/www.ainvest.com\/news\/mediwound-mdwd-q2-2025-earnings-strategic-progress-rising-losses-balancing-act-risk-reward-2508\/\">AInvest Analizi<\/a>)<\/li> <\/ul> <h3>Reg\u00fclasyon Zorluklar\u0131<\/h3> <ul> <li>FDA onay s\u00fcre\u00e7leri \u00fcr\u00fcn lansmanlar\u0131n\u0131 geciktirebilir<\/li> <li>\u00dcretim tesisinin \u00f6l\u00e7eklendirilmesi reg\u00fclasyon onaylar\u0131 gerektirir<\/li> <li>Sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131lar\u0131ndan geri \u00f6deme zorluklar\u0131<\/li> <\/ul> <h3>Rekabet Bask\u0131lar\u0131<\/h3> <ul> <li>Daha derin kaynaklara sahip b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li> <li>Alternatif yara bak\u0131m teknolojilerinin ortaya \u00e7\u0131kmas\u0131<\/li> <li>Sa\u011fl\u0131k sekt\u00f6r\u00fcnde fiyat bask\u0131lar\u0131<\/li> <\/ul> <h2>\ud83d\udfe2 Olumlu Sinyaller: Yat\u0131r\u0131mc\u0131lar\u0131n Heyecanlanma Nedenleri<\/h2> <ul> <li><strong>Gelir H\u0131z\u0131<\/strong>: %43 \u00e7eyreklik b\u00fcy\u00fcme ticari \u00e7eki\u015f g\u00f6steriyor<\/li> <li><strong>Br\u00fct Kar Marj\u0131 Geni\u015flemesi<\/strong>: Y\u0131ll\u0131k %8,8'den %23,5'e iyile\u015fme<\/li> <li><strong>Stratejik Ortakl\u0131klar<\/strong>: ConvaTec, Essity ve di\u011fer sekt\u00f6r liderleriyle anla\u015fmalar<\/li> <li><strong>Devlet Deste\u011fi<\/strong>: NexoBrid geli\u015ftirmesi i\u00e7in 3,6M $ Savunma Bakanl\u0131\u011f\u0131 fonu<\/li> <li><strong>Pazar Konumu<\/strong>: 2,5 milyar $ kronik yara pazar\u0131 f\u0131rsat\u0131n\u0131 hedefliyor<\/li> <\/ul> <h2>\ud83d\udcf0 \u00d6nemli Haberler: Son 6 Ay Analizi<\/h2> <ul> <li><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 etkileyici gelir art\u0131\u015f\u0131 g\u00f6sterdi ancak Ar-Ge yat\u0131r\u0131mlar\u0131 nedeniyle zararlar geni\u015fledi<\/li> <li><strong>Temmuz 2025<\/strong>: Y\u0131l sonuna kadar kapasiteyi alt\u0131 kat art\u0131racak \u00fcretim \u00f6l\u00e7eklendirmesi duyuruldu<\/li> <li><strong>Haziran 2025<\/strong>: Ek Savunma Bakanl\u0131\u011f\u0131 fonu al\u0131nd\u0131 ve konferanslarda olumlu klinik veriler sunuldu<\/li> <li><strong>May\u0131s 2025<\/strong>: Analist y\u00fckseltmeleri ve stratejik ortakl\u0131k duyurular\u0131<\/li> <li><strong>Nisan 2025<\/strong>: Faz II verileri EscharEx'in mevcut tedavilere \u00fcst\u00fcnl\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi<\/li> <\/ul> <p>Her haber olay\u0131, hisse senedinde genellikle artan hacim ve volatilite ile ticaret f\u0131rsatlar\u0131 yaratt\u0131.<\/p> <h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2> <h3>Ciddi \u00d6neriler:<\/h3> <ol> <li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3'\u00fcnden fazlas\u0131n\u0131 MDWD'ye ay\u0131rmay\u0131n\u2014buras\u0131 y\u00fcksek riskli biyoteknoloji<\/li> <li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine birka\u00e7 ayda k\u00fc\u00e7\u00fck pozisyonlar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li> <li><strong>25 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun<\/li> <\/ol> <p><strong>Eski Bir T\u00fcccardan Mizahi Bak\u0131\u015f<\/strong>: \"MDWD ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz heyecan verici ama beklenmedik deneylere ve ara s\u0131ra laboratuvarda patlamalara haz\u0131rl\u0131kl\u0131 olun. At\u0131l\u0131mlar hayat de\u011fi\u015ftirebilir, ancak asbest eldivenler ve yang\u0131n s\u00f6nd\u00fcr\u00fcc\u00fc elinizin alt\u0131nda olmal\u0131!\"<\/p> <h2>\u2705 MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - Ad\u0131m Ad\u0131m<\/h2> <table border=\"1\" cellpadding=\"5\" cellspacing=\"0\"> <thead> <tr> <th>Ad\u0131m<\/th> <th>\u0130\u015flem<\/th> <th>Neden \u00d6nemli<\/th> <\/tr> <\/thead> <tbody> <tr> <td>1<\/td> <td>Bir Ticaret Platformu Se\u00e7in<\/td> <td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td> <\/tr> <tr> <td>2<\/td> <td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td> <td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td> <\/tr> <tr> <td>3<\/td> <td>Fon Yat\u0131r\u0131n<\/td> <td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td> <\/tr> <tr> <td>4<\/td> <td>\"MDWD\" Aray\u0131n<\/td> <td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td> <\/tr> <tr> <td>5<\/td> <td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td> <td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td> <\/tr> <tr> <td>6<\/td> <td>\u0130nceleyin ve Onaylay\u0131n<\/td> <td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td> <\/tr> <tr> <td>7<\/td> <td>Pozisyonunuzu \u0130zleyin<\/td> <td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td> <\/tr> <\/tbody> <\/table> <h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2> <p>MediWound Ltd. (MDWD) hissesine yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, \u00f6zellikle yeni ba\u015flayanlar i\u00e7in birka\u00e7 avantaj sunar:<\/p> <ul> <li><strong>En D\u00fc\u015f\u00fck Minimum Yat\u0131r\u0131m<\/strong>: Sadece 5 $ ile ba\u015flayarak, MediWound gibi umut vadeden \u015firketlere maruz kal\u0131rken yat\u0131r\u0131m stratejinizi minimal riskle test edebilirsiniz.<\/li> <li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Platformun sadele\u015ftirilmi\u015f KYC s\u00fcreci herhangi bir tek devlet kimli\u011fi kabul eder, b\u00f6ylece g\u00fcnler yerine dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li> <li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100'den fazla para \u00e7ekme y\u00f6ntemi, karlar\u0131n\u0131z\u0131 kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k tercihlerinize g\u00f6re kolayca eri\u015fmenizi sa\u011flar.<\/li> <\/ul> <p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k ticaret sistemlerinde gezinmek yerine \u015firket analizine odaklanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p> <h2>\ud83c\udf0d 2025'te MediWound: Yara Bak\u0131m\u0131nda Yenilik Lideri<\/h2> <p>MediWound, amiral gemisi \u00fcr\u00fcn\u00fc NexoBrid ile \u00f6nemli gelirler elde eden ve ara\u015ft\u0131rma tedavisi EscharEx ile klinik denemelerde b\u00fcy\u00fck umut vadeden enzimatik yara bak\u0131m teknolojisinin \u00f6nc\u00fcs\u00fcd\u00fcr. ConvaTec ve Essity gibi sekt\u00f6r devleriyle stratejik ortakl\u0131klar\u0131, do\u011frulama sa\u011flar ve ticarile\u015fme riskini azalt\u0131r.<\/p> <p><strong>Mevcut Pazar Konumu<\/strong>: MediWound, klinik denemelerde mevcut tedavilere \u00fcst\u00fcnl\u00fck g\u00f6steren \u00fcr\u00fcnleriyle 2,5 milyar $ kronik yara debridman pazar\u0131nda yenilik\u00e7i teknoloji kontrol\u00fc sa\u011fl\u0131yor (<a href=\"https:\/\/mediwound.com\/wp-content\/uploads\/2025\/08\/MDWD-corporate-deck-August-2025-1.pdf\">Kurumsal Sunum<\/a>).<\/p> <p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: MediWound'un \u00fcretim geni\u015flemesi sadece kapasiteyle ilgili de\u011fil\u2014ayn\u0131 zamanda hassasiyetle ilgili. Yeni tesisi, enzim tutarl\u0131l\u0131\u011f\u0131ndaki mikroskobik varyasyonlar\u0131 tespit edebilen yapay zeka destekli kalite kontrol sistemleri kullan\u0131yor ve b\u00f6ylece her parti tam t\u0131bbi standartlara uygun oluyor. Bu teknolojik avantaj, onlar\u0131 daha b\u00fcy\u00fck rakiplere kar\u015f\u0131 gizli silahlar\u0131 haline getirebilir!<\/p>","body_html_source":{"label":"Body HTML","type":"wysiwyg","formatted_value":"<h2>\ud83d\udcc8 G\u00fcncel Hisse Fiyat\u0131 ve Kritik Tarihler<\/h2>\n<p>29 A\u011fustos 2025 itibar\u0131yla, MediWound Ltd. (MDWD) NASDAQ borsas\u0131nda <strong>17,25 $<\/strong> seviyesinden i\u015flem g\u00f6r\u00fcyor. Takviminize i\u015faretleyin: <strong>25 Kas\u0131m 2025<\/strong> kesinlikle kritik\u2014\u015firketin 3. \u00e7eyrek kazan\u00e7 raporunu yay\u0131nlayaca\u011f\u0131 tarih.<\/p>\n<h3>25 Kas\u0131m Neden Bu Kadar \u00d6nemli<\/h3>\n<p>MediWound, kazan\u00e7 tarihleri \u00e7evresinde dramatik fiyat hareketleri g\u00f6sterdi. \u015eirketin 14 A\u011fustos 2025&#8217;teki son 2. \u00e7eyrek raporu, g\u00fc\u00e7l\u00fc %43 \u00e7eyrekten \u00e7eyre\u011fe gelir art\u0131\u015f\u0131yla 5,7 milyon $&#8217;a ula\u015fmas\u0131na ra\u011fmen \u00f6nemli volatiliteye neden oldu (<a href=\"https:\/\/www.nasdaq.com\/articles\/mediwound-revenue-jumps-43-q2\">Nasdaq Raporu<\/a>).<\/p>\n<p>Tarihsel kazan\u00e7 tepkileri ilgin\u00e7 bir desen ortaya koyuyor:<\/p>\n<ul>\n<li><strong>2025 2. \u00c7eyrek (14 A\u011fu)<\/strong>: Gelir beklentileri a\u015fmas\u0131na ra\u011fmen, net zararlar\u0131n geni\u015flemesi nedeniyle hisse bask\u0131 alt\u0131nda kald\u0131<\/li>\n<li><strong>2025 1. \u00c7eyrek (21 May)<\/strong>: EPS -0,07 ile -0,66 tahminlerini %89,39 a\u015farak olumlu kazan\u00e7 s\u00fcrprizi<\/li>\n<li><strong>2024 4. \u00c7eyrek (19 Mar)<\/strong>: Beklentileri %40,98 a\u015fmas\u0131na ra\u011fmen hemen fiyat \u00fczerinde s\u0131n\u0131rl\u0131 etki<\/li>\n<\/ul>\n<p>Bu desen, MediWound&#8217;un genellikle kazan\u00e7 tahminlerini a\u015fmas\u0131na ra\u011fmen, piyasan\u0131n \u00e7eyreklik finansal metriklerden ziyade uzun vadeli klinik geli\u015fmelere daha g\u00fc\u00e7l\u00fc tepki verdi\u011fini g\u00f6steriyor.<\/p>\n<div class=\"po-container po-container_width_article\">\n   <div class=\"po-cta-green__wrap\">\n      <a href=\"https:\/\/pocketoption.com\/tr\/register\/\" class=\"po-cta-green\">Ticarete Ba\u015fla\n         <span class=\"po-cta-green__icon\">\n            <svg width=\"24\" height=\"24\" fill=\"none\" aria-hidden=\"true\">\n               <use href=\"#svg-arrow-cta\"><\/use>\n            <\/svg>\n         <\/span>\n      <\/a>\n   <\/div>\n<\/div>\n<h2>\ud83d\udcca 6 Ayl\u0131k Fiyat Yolculu\u011fu: Ama\u00e7l\u0131 Bir Rollercoaster<\/h2>\n<p>MediWound&#8217;un hissesi son alt\u0131 ayda klinik a\u015famadaki biyoteknoloji \u015firketlerine \u00f6zg\u00fc \u00f6nemli volatilite ya\u015fad\u0131:<\/p>\n<ul>\n<li><strong>\u015eubat-Mart 2025<\/strong>: Yat\u0131r\u0131mc\u0131lar 4. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 beklerken hisse 14-16 $ aral\u0131\u011f\u0131nda i\u015flem g\u00f6rd\u00fc<\/li>\n<li><strong>Nisan-May\u0131s 2025<\/strong>: Olumlu 1. \u00e7eyrek kazan\u00e7 s\u00fcrprizi sonras\u0131 18-20 $ aral\u0131\u011f\u0131na s\u0131\u00e7rad\u0131<\/li>\n<li><strong>Haziran-Temmuz 2025<\/strong>: Piyasa \u00fcretim geni\u015fleme haberlerini sindirirken 17-19 $ civar\u0131nda konsolide oldu<\/li>\n<li><strong>A\u011fustos 2025<\/strong>: Mevcut 17,25 $ seviyesi kar\u0131\u015f\u0131k 2. \u00e7eyrek sonu\u00e7lar\u0131n\u0131 yans\u0131t\u0131yor\u2014g\u00fc\u00e7l\u00fc gelir ama daha geni\u015f zararlar<\/li>\n<\/ul>\n<p>Genel e\u011filim <strong>%17,70 ayl\u0131k d\u00fc\u015f\u00fc\u015f<\/strong> g\u00f6sterse de, bu durum \u015firketin gelecekteki b\u00fcy\u00fcmeye a\u011f\u0131r yat\u0131r\u0131m yapt\u0131\u011f\u0131n\u0131 gizliyor (<a href=\"https:\/\/www.tradingview.com\/symbols\/NASDAQ-MDWD\/\">TradingView Verileri<\/a>). Bu volatilite, dikkatli yat\u0131r\u0131mc\u0131lar i\u00e7in hem risk hem de f\u0131rsat yarat\u0131yor.<\/p>\n<h2>\ud83d\udd2e Fiyat Tahmini: 2025-2030 G\u00f6r\u00fcn\u00fcm\u00fc<\/h2>\n<p>Mevcut analist konsens\u00fcs\u00fc ve klinik d\u00f6n\u00fcm noktalar\u0131na dayanarak, gelecekte neler olabilece\u011fine dair \u00f6ng\u00f6r\u00fcler:<\/p>\n<ul>\n<li><strong>2025 Y\u0131l Sonu<\/strong>: 25-30 $ aral\u0131\u011f\u0131 (%45-75 y\u00fckseli\u015f potansiyeli)\n<ul>\n<li>\u00dcretim \u00f6l\u00e7eklendirme tamamlanmas\u0131yla destekleniyor<\/li>\n<li>EscharEx Faz III deneme ilerleme g\u00fcncellemeleri<\/li>\n<li>Olas\u0131 ortakl\u0131k geni\u015flemeleri<\/li>\n<\/ul>\n<\/li>\n<li><strong>2026 Hedefi<\/strong>: 35-40 $ aral\u0131\u011f\u0131\n<ul>\n<li>EscharEx Faz III verilerinin 2026 ortas\u0131nda beklenmesi kritik y\u0131l<\/li>\n<li>\u00dcretim kapasitesinin tam kullan\u0131m\u0131<\/li>\n<li>Olas\u0131 uluslararas\u0131 pazar geni\u015flemeleri<\/li>\n<\/ul>\n<\/li>\n<li><strong>2028 Projeksiyonu<\/strong>: 50-60 $ aral\u0131\u011f\u0131\n<ul>\n<li>EscharEx&#8217;in ba\u015far\u0131l\u0131 ticarile\u015fmesi varsay\u0131m\u0131<\/li>\n<li>Kronik yara bak\u0131m segmentinde pazar penetrasyonu<\/li>\n<li>Olas\u0131 ek \u00fcr\u00fcn hatt\u0131 geli\u015fmeleri<\/li>\n<\/ul>\n<\/li>\n<li><strong>2030 Vizyonu<\/strong>: 75-100+ $ aral\u0131\u011f\u0131\n<ul>\n<li>Enzimatik debridman alan\u0131nda yerle\u015fik liderlik<\/li>\n<li>B\u00fcy\u00fck ila\u00e7 \u015firketleri i\u00e7in potansiyel sat\u0131n alma hedefi<\/li>\n<li>\u00c7oklu endikasyonlarda k\u00fcresel pazar geni\u015flemesi<\/li>\n<\/ul>\n<\/li>\n<\/ul>\n<p><strong>Sonu\u00e7<\/strong>: 2-3 y\u0131ll\u0131k ufku olan risk tolerans\u0131 y\u00fcksek yat\u0131r\u0131mc\u0131lar i\u00e7in G\u00dc\u00c7L\u00dc ALIM<\/p>\n<h2>\u26a0\ufe0f Risk De\u011ferlendirmesi: Yat\u0131r\u0131m Yapmadan \u00d6nce Bilin<\/h2>\n<h3>Y\u00fcksek Volatilite Riskleri<\/h3>\n<ul>\n<li>Biyoteknoloji hisseleri tek haber olaylar\u0131nda %20-30 dalgalanabilir<\/li>\n<li>Klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131 hisse fiyat\u0131n\u0131 y\u0131kabilir<\/li>\n<li>32,9M $ nakit t\u00fcketimi sadece 16-18 ayl\u0131k \u00e7al\u0131\u015fma sermayesi sa\u011fl\u0131yor (<a href=\"https:\/\/www.ainvest.com\/news\/mediwound-mdwd-q2-2025-earnings-strategic-progress-rising-losses-balancing-act-risk-reward-2508\/\">AInvest Analizi<\/a>)<\/li>\n<\/ul>\n<h3>Reg\u00fclasyon Zorluklar\u0131<\/h3>\n<ul>\n<li>FDA onay s\u00fcre\u00e7leri \u00fcr\u00fcn lansmanlar\u0131n\u0131 geciktirebilir<\/li>\n<li>\u00dcretim tesisinin \u00f6l\u00e7eklendirilmesi reg\u00fclasyon onaylar\u0131 gerektirir<\/li>\n<li>Sa\u011fl\u0131k hizmeti sa\u011flay\u0131c\u0131lar\u0131ndan geri \u00f6deme zorluklar\u0131<\/li>\n<\/ul>\n<h3>Rekabet Bask\u0131lar\u0131<\/h3>\n<ul>\n<li>Daha derin kaynaklara sahip b\u00fcy\u00fck ila\u00e7 \u015firketleri<\/li>\n<li>Alternatif yara bak\u0131m teknolojilerinin ortaya \u00e7\u0131kmas\u0131<\/li>\n<li>Sa\u011fl\u0131k sekt\u00f6r\u00fcnde fiyat bask\u0131lar\u0131<\/li>\n<\/ul>\n<h2>\ud83d\udfe2 Olumlu Sinyaller: Yat\u0131r\u0131mc\u0131lar\u0131n Heyecanlanma Nedenleri<\/h2>\n<ul>\n<li><strong>Gelir H\u0131z\u0131<\/strong>: %43 \u00e7eyreklik b\u00fcy\u00fcme ticari \u00e7eki\u015f g\u00f6steriyor<\/li>\n<li><strong>Br\u00fct Kar Marj\u0131 Geni\u015flemesi<\/strong>: Y\u0131ll\u0131k %8,8&#8217;den %23,5&#8217;e iyile\u015fme<\/li>\n<li><strong>Stratejik Ortakl\u0131klar<\/strong>: ConvaTec, Essity ve di\u011fer sekt\u00f6r liderleriyle anla\u015fmalar<\/li>\n<li><strong>Devlet Deste\u011fi<\/strong>: NexoBrid geli\u015ftirmesi i\u00e7in 3,6M $ Savunma Bakanl\u0131\u011f\u0131 fonu<\/li>\n<li><strong>Pazar Konumu<\/strong>: 2,5 milyar $ kronik yara pazar\u0131 f\u0131rsat\u0131n\u0131 hedefliyor<\/li>\n<\/ul>\n<h2>\ud83d\udcf0 \u00d6nemli Haberler: Son 6 Ay Analizi<\/h2>\n<ul>\n<li><strong>A\u011fustos 2025<\/strong>: 2. \u00e7eyrek kazan\u00e7lar\u0131 etkileyici gelir art\u0131\u015f\u0131 g\u00f6sterdi ancak Ar-Ge yat\u0131r\u0131mlar\u0131 nedeniyle zararlar geni\u015fledi<\/li>\n<li><strong>Temmuz 2025<\/strong>: Y\u0131l sonuna kadar kapasiteyi alt\u0131 kat art\u0131racak \u00fcretim \u00f6l\u00e7eklendirmesi duyuruldu<\/li>\n<li><strong>Haziran 2025<\/strong>: Ek Savunma Bakanl\u0131\u011f\u0131 fonu al\u0131nd\u0131 ve konferanslarda olumlu klinik veriler sunuldu<\/li>\n<li><strong>May\u0131s 2025<\/strong>: Analist y\u00fckseltmeleri ve stratejik ortakl\u0131k duyurular\u0131<\/li>\n<li><strong>Nisan 2025<\/strong>: Faz II verileri EscharEx&#8217;in mevcut tedavilere \u00fcst\u00fcnl\u00fc\u011f\u00fcn\u00fc g\u00f6sterdi<\/li>\n<\/ul>\n<p>Her haber olay\u0131, hisse senedinde genellikle artan hacim ve volatilite ile ticaret f\u0131rsatlar\u0131 yaratt\u0131.<\/p>\n<h2>\ud83c\udfaf Yeni Ba\u015flayanlar \u0130\u00e7in Bug\u00fcnk\u00fc \u0130\u015flem Plan\u0131<\/h2>\n<h3>Ciddi \u00d6neriler:<\/h3>\n<ol>\n<li><strong>K\u00fc\u00e7\u00fck Ba\u015flay\u0131n<\/strong>: Portf\u00f6y\u00fcn\u00fcz\u00fcn %2-3&#8217;\u00fcnden fazlas\u0131n\u0131 MDWD&#8217;ye ay\u0131rmay\u0131n\u2014buras\u0131 y\u00fcksek riskli biyoteknoloji<\/li>\n<li><strong>Dolar Maliyet Ortalamas\u0131<\/strong>: Tek seferde b\u00fcy\u00fck al\u0131m yerine birka\u00e7 ayda k\u00fc\u00e7\u00fck pozisyonlar almay\u0131 d\u00fc\u015f\u00fcn\u00fcn<\/li>\n<li><strong>25 Kas\u0131m \u0130\u00e7in Uyar\u0131 Kurun<\/strong>: Kazan\u00e7 tarihini i\u015faretleyin ve olas\u0131 volatiliteye haz\u0131rl\u0131kl\u0131 olun<\/li>\n<\/ol>\n<p><strong>Eski Bir T\u00fcccardan Mizahi Bak\u0131\u015f<\/strong>: &#8220;MDWD ile i\u015flem yapmak, parlak bir bilim insan\u0131yla \u00e7\u0131kmak gibidir\u2014inan\u0131lmaz heyecan verici ama beklenmedik deneylere ve ara s\u0131ra laboratuvarda patlamalara haz\u0131rl\u0131kl\u0131 olun. At\u0131l\u0131mlar hayat de\u011fi\u015ftirebilir, ancak asbest eldivenler ve yang\u0131n s\u00f6nd\u00fcr\u00fcc\u00fc elinizin alt\u0131nda olmal\u0131!&#8221;<\/p>\n<h2>\u2705 MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; Ad\u0131m Ad\u0131m<\/h2>\n<table border=\"1\" cellpadding=\"5\" cellspacing=\"0\">\n<thead>\n<tr>\n<th>Ad\u0131m<\/th>\n<th>\u0130\u015flem<\/th>\n<th>Neden \u00d6nemli<\/th>\n<\/tr>\n<\/thead>\n<tbody>\n<tr>\n<td>1<\/td>\n<td>Bir Ticaret Platformu Se\u00e7in<\/td>\n<td>NASDAQ eri\u015fimi ve makul \u00fccretler sundu\u011fundan emin olun<\/td>\n<\/tr>\n<tr>\n<td>2<\/td>\n<td>Hesap Do\u011frulamas\u0131n\u0131 Tamamlay\u0131n<\/td>\n<td>Genellikle kimlik ve adres kan\u0131t\u0131 gerektirir<\/td>\n<\/tr>\n<tr>\n<td>3<\/td>\n<td>Fon Yat\u0131r\u0131n<\/td>\n<td>Risk almaya haz\u0131r oldu\u011funuz bir miktarla ba\u015flay\u0131n<\/td>\n<\/tr>\n<tr>\n<td>4<\/td>\n<td>&#8220;MDWD&#8221; Aray\u0131n<\/td>\n<td>Sadece \u015firket ad\u0131 de\u011fil, sembol\u00fc kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>5<\/td>\n<td>Emir T\u00fcr\u00fcn\u00fc Se\u00e7in<\/td>\n<td>Giri\u015f fiyat\u0131n\u0131z\u0131 kontrol etmek i\u00e7in limit emirleri kullan\u0131n<\/td>\n<\/tr>\n<tr>\n<td>6<\/td>\n<td>\u0130nceleyin ve Onaylay\u0131n<\/td>\n<td>Komisyon \u00fccretleri ve toplam maliyeti kontrol edin<\/td>\n<\/tr>\n<tr>\n<td>7<\/td>\n<td>Pozisyonunuzu \u0130zleyin<\/td>\n<td>\u00d6nemli seviyeler i\u00e7in fiyat uyar\u0131lar\u0131 kurun<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<h2>\ud83d\udca1 Yeni Yat\u0131r\u0131mc\u0131lar \u0130\u00e7in Pocket Option Neden Mant\u0131kl\u0131<\/h2>\n<p>MediWound Ltd. (MDWD) hissesine yat\u0131r\u0131m yapmak isteyenler i\u00e7in Pocket Option, \u00f6zellikle yeni ba\u015flayanlar i\u00e7in birka\u00e7 avantaj sunar:<\/p>\n<ul>\n<li><strong>En D\u00fc\u015f\u00fck Minimum Yat\u0131r\u0131m<\/strong>: Sadece 5 $ ile ba\u015flayarak, MediWound gibi umut vadeden \u015firketlere maruz kal\u0131rken yat\u0131r\u0131m stratejinizi minimal riskle test edebilirsiniz.<\/li>\n<li><strong>H\u0131zl\u0131 Do\u011frulama<\/strong>: Platformun sadele\u015ftirilmi\u015f KYC s\u00fcreci herhangi bir tek devlet kimli\u011fi kabul eder, b\u00f6ylece g\u00fcnler yerine dakikalar i\u00e7inde i\u015flem yapmaya ba\u015flayabilirsiniz.<\/li>\n<li><strong>\u00c7e\u015fitli Para \u00c7ekme Se\u00e7enekleri<\/strong>: 100&#8217;den fazla para \u00e7ekme y\u00f6ntemi, karlar\u0131n\u0131z\u0131 kripto, e-c\u00fczdan veya geleneksel bankac\u0131l\u0131k tercihlerinize g\u00f6re kolayca eri\u015fmenizi sa\u011flar.<\/li>\n<\/ul>\n<p>Platformun kullan\u0131c\u0131 dostu aray\u00fcz\u00fc, karma\u015f\u0131k ticaret sistemlerinde gezinmek yerine \u015firket analizine odaklanmak isteyen yat\u0131r\u0131mc\u0131lar i\u00e7in idealdir.<\/p>\n<h2>\ud83c\udf0d 2025&#8217;te MediWound: Yara Bak\u0131m\u0131nda Yenilik Lideri<\/h2>\n<p>MediWound, amiral gemisi \u00fcr\u00fcn\u00fc NexoBrid ile \u00f6nemli gelirler elde eden ve ara\u015ft\u0131rma tedavisi EscharEx ile klinik denemelerde b\u00fcy\u00fck umut vadeden enzimatik yara bak\u0131m teknolojisinin \u00f6nc\u00fcs\u00fcd\u00fcr. ConvaTec ve Essity gibi sekt\u00f6r devleriyle stratejik ortakl\u0131klar\u0131, do\u011frulama sa\u011flar ve ticarile\u015fme riskini azalt\u0131r.<\/p>\n<p><strong>Mevcut Pazar Konumu<\/strong>: MediWound, klinik denemelerde mevcut tedavilere \u00fcst\u00fcnl\u00fck g\u00f6steren \u00fcr\u00fcnleriyle 2,5 milyar $ kronik yara debridman pazar\u0131nda yenilik\u00e7i teknoloji kontrol\u00fc sa\u011fl\u0131yor (<a href=\"https:\/\/mediwound.com\/wp-content\/uploads\/2025\/08\/MDWD-corporate-deck-August-2025-1.pdf\">Kurumsal Sunum<\/a>).<\/p>\n<p><strong>2025 \u0130\u00e7in \u0130lgin\u00e7 Bir Ger\u00e7ek<\/strong>: MediWound&#8217;un \u00fcretim geni\u015flemesi sadece kapasiteyle ilgili de\u011fil\u2014ayn\u0131 zamanda hassasiyetle ilgili. Yeni tesisi, enzim tutarl\u0131l\u0131\u011f\u0131ndaki mikroskobik varyasyonlar\u0131 tespit edebilen yapay zeka destekli kalite kontrol sistemleri kullan\u0131yor ve b\u00f6ylece her parti tam t\u0131bbi standartlara uygun oluyor. Bu teknolojik avantaj, onlar\u0131 daha b\u00fcy\u00fck rakiplere kar\u015f\u0131 gizli silahlar\u0131 haline getirebilir!<\/p>\n"},"faq":[{"question":"MediWound Ltd. hisseleri nereden al\u0131nabilir?","answer":"MediWound Ltd. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"MediWound hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma g\u00f6re de\u011fi\u015fir. \u00d6rne\u011fin, Pocket Option platformunda sadece 5 $ ile yat\u0131r\u0131m yapmaya ba\u015flayabilirsiniz."},{"question":"MediWound hisselerinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon gecikmeleri ve rekabet bask\u0131lar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"MediWound hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 25-30 $, 2026'da 35-40 $, 2028'de 50-60 $ ve 2030'da 75-100 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"MediWound hisseleri i\u00e7in yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, dolar maliyet ortalamas\u0131 yapmak ve \u00f6nemli kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar kurmak \u00f6nemlidir."}],"faq_source":{"label":"FAQ","type":"repeater","formatted_value":[{"question":"MediWound Ltd. hisseleri nereden al\u0131nabilir?","answer":"MediWound Ltd. hisseleri NASDAQ borsas\u0131nda i\u015flem g\u00f6rmektedir. G\u00fcvenilir bir arac\u0131 kurum veya online ticaret platformu \u00fczerinden sat\u0131n alabilirsiniz."},{"question":"MediWound hisseleri almak i\u00e7in minimum yat\u0131r\u0131m tutar\u0131 nedir?","answer":"Minimum yat\u0131r\u0131m tutar\u0131 se\u00e7ti\u011finiz platforma g\u00f6re de\u011fi\u015fir. \u00d6rne\u011fin, Pocket Option platformunda sadece 5 $ ile yat\u0131r\u0131m yapmaya ba\u015flayabilirsiniz."},{"question":"MediWound hisselerinin riskleri nelerdir?","answer":"Y\u00fcksek volatilite, klinik deneme ba\u015far\u0131s\u0131zl\u0131klar\u0131, reg\u00fclasyon gecikmeleri ve rekabet bask\u0131lar\u0131 ba\u015fl\u0131ca risklerdir."},{"question":"MediWound hisseleri i\u00e7in fiyat tahmini nedir?","answer":"Analistlere g\u00f6re 2025 sonunda 25-30 $, 2026'da 35-40 $, 2028'de 50-60 $ ve 2030'da 75-100 $ aral\u0131\u011f\u0131nda fiyatlar beklenmektedir."},{"question":"MediWound hisseleri i\u00e7in yat\u0131r\u0131m yaparken nelere dikkat etmeliyim?","answer":"Portf\u00f6y\u00fcn\u00fcz\u00fcn k\u00fc\u00e7\u00fck bir k\u0131sm\u0131n\u0131 ay\u0131rmak, dolar maliyet ortalamas\u0131 yapmak ve \u00f6nemli kazan\u00e7 tarihleri i\u00e7in uyar\u0131lar kurmak \u00f6nemlidir."}]}},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v24.8 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\" \/>\n<meta property=\"og:locale\" content=\"tr_TR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131\" \/>\n<meta property=\"og:description\" content=\"text\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\" \/>\n<meta property=\"og:site_name\" content=\"Pocket Option blog\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-29T10:30:32+00:00\" \/>\n<meta name=\"author\" content=\"Signal\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Yazan:\" \/>\n\t<meta name=\"twitter:data1\" content=\"Signal\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\"},\"author\":{\"name\":\"Signal\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"headline\":\"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"datePublished\":\"2025-08-29T10:30:32+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\"},\"wordCount\":19,\"commentCount\":0,\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"keywords\":[\"signal\"],\"articleSection\":[\"Signals\"],\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#respond\"]}]},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\",\"name\":\"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131\",\"isPartOf\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"datePublished\":\"2025-08-29T10:30:32+00:00\",\"author\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\"},\"breadcrumb\":{\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#breadcrumb\"},\"inLanguage\":\"tr\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage\",\"url\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"contentUrl\":\"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp\",\"width\":1024,\"height\":576},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/pocketoption.com\/blog\/tr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#website\",\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/\",\"name\":\"Pocket Option blog\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"tr\"},{\"@type\":\"Person\",\"@id\":\"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe\",\"name\":\"Signal\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"tr\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g\",\"caption\":\"Signal\"},\"url\":\"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/","og_locale":"tr_TR","og_type":"article","og_title":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131","og_description":"text","og_url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/","og_site_name":"Pocket Option blog","article_published_time":"2025-08-29T10:30:32+00:00","author":"Signal","twitter_card":"summary_large_image","twitter_misc":{"Yazan:":"Signal"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#article","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/"},"author":{"name":"Signal","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"headline":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131","datePublished":"2025-08-29T10:30:32+00:00","mainEntityOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/"},"wordCount":19,"commentCount":0,"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","keywords":["signal"],"articleSection":["Signals"],"inLanguage":"tr","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#respond"]}]},{"@type":"WebPage","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/","url":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/","name":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r - MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131","isPartOf":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage"},"image":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage"},"thumbnailUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","datePublished":"2025-08-29T10:30:32+00:00","author":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe"},"breadcrumb":{"@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#breadcrumb"},"inLanguage":"tr","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/"]}]},{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#primaryimage","url":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","contentUrl":"https:\/\/pocketoption.com\/blog\/wp-content\/uploads\/2025\/08\/banner_signals3.webp","width":1024,"height":576},{"@type":"BreadcrumbList","@id":"https:\/\/pocketoption.com\/blog\/tr\/news-events\/signal\/how-to-buy-mediwound\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/pocketoption.com\/blog\/tr\/"},{"@type":"ListItem","position":2,"name":"MediWound Ltd. (MDWD) Hisseleri Nas\u0131l Al\u0131n\u0131r &#8211; MediWound Ltd. (MDWD) Hisse Senedi Yat\u0131r\u0131m\u0131"}]},{"@type":"WebSite","@id":"https:\/\/pocketoption.com\/blog\/tr\/#website","url":"https:\/\/pocketoption.com\/blog\/tr\/","name":"Pocket Option blog","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pocketoption.com\/blog\/tr\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"tr"},{"@type":"Person","@id":"https:\/\/pocketoption.com\/blog\/tr\/#\/schema\/person\/0011214e4ecd8db385a5d71d6f28bfbe","name":"Signal","image":{"@type":"ImageObject","inLanguage":"tr","@id":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/e9506d2276dd67fbab5410249d21aea3e629528f720f69eb67c73bcf2a446ebd?s=96&d=mm&r=g","caption":"Signal"},"url":"https:\/\/pocketoption.com\/blog\/tr\/author\/signal\/"}]}},"po_author":null,"po__editor":null,"po_last_edited":null,"wpml_current_locale":"tr_TR","wpml_translations":{"vt_VT":{"locale":"vt_VT","id":357461,"slug":"how-to-buy-mediwound","post_title":"C\u00e1ch mua c\u1ed5 phi\u1ebfu MediWound Ltd. (MDWD) - \u0110\u1ea7u t\u01b0 v\u00e0o c\u1ed5 phi\u1ebfu MediWound Ltd. (MDWD)","href":"https:\/\/pocketoption.com\/blog\/vt\/news-events\/signal\/how-to-buy-mediwound\/"},"pt_AA":{"locale":"pt_AA","id":357462,"slug":"how-to-buy-mediwound","post_title":"Como comprar a\u00e7\u00f5es da MediWound Ltd. (MDWD) - Investimento em a\u00e7\u00f5es da MediWound Ltd. (MDWD)","href":"https:\/\/pocketoption.com\/blog\/pt\/news-events\/signal\/how-to-buy-mediwound\/"}},"_links":{"self":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357457","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/users\/129"}],"replies":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/comments?post=357457"}],"version-history":[{"count":0,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/posts\/357457\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media\/334009"}],"wp:attachment":[{"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/media?parent=357457"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/categories?post=357457"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pocketoption.com\/blog\/tr\/wp-json\/wp\/v2\/tags?post=357457"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}